Top Story

Biomarkers predicted mortality in patients with acetaminophen-induced ALF

September 30, 2014

Specific mitochondrial biomarker serum levels were greater among patients who did not survive acetaminophen-induced acute liver failure compared with those who survived and recovered, according to new study data.

Serum samples of glutamate dehydrogenase (GDH), mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) were taken from patients enrolled in the Acute Liver Failure Study Group network who survived acetaminophen (APAP)-induced acute liver failure (ALF; n=34) and compared with levels of those who died (n=35). A healthy control cohort also was used for comparison.

figure

Medical societies express concern as CMS publishes first wave of payment data

September 30, 2014
CMS has come under criticism today for the release of its first batch of Open Payments System data. According to some medical societies, the data are inaccurate and…

Potential liver repair drug CF102 issued US patent

September 30, 2014
Can-Fite BioPharma received a US patent for CF102, a drug under development to repair liver cells and function in patients with hepatocellular carcinoma, according to a…

Proposition 46 under fire: Experts call for better approach to physician drug testing

September 29, 2014
In two editorials published in the Annals of Internal Medicine, three physicians are speaking out against California’s Proposition 46, which would require…
More News Headlines »
CME
figure

HCV Consults: Volume 1, Number 1

This activity is supported by educational grants from AbbVie and Genentech.

Physicians seldom experience a paradigm shift in disease management as great as that transpiring in HCV therapy. With…
More »
Meeting News Coverage Video
figure

Tenofovir/entecavir recommended for HBV patients with malignancy

May 16, 2014
CHICAGO — Spilios Manolakopoulos, MD, of the internal medicine and hepatology departments at…
More »
CME
figure

HCV Consults: Volume 1, Number 2

This activity is supported by educational grants from AbbVie and Genentech.

Approved interferon-free therapy has already become entrenched among clinicians for patients with HCV genotypes 2 and…
More »